An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants with Relapsed or Refractory Ewing Sarcoma
Study of Drug (INCB059872) in Participants with Relapsed or Refractory Ewing Sarcoma
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAR7289
U.S. Govt. ID: NCT03514407
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of this research study is to test different doses of INCB059872 and see which doses are safe and tolerable in participants that have Ewing sarcoma. This study will research the effect that INCB059872 has on your cancer. Researchers will study the way INCB059872 come into and leave your body over time (pharmacokinetics). INCB059872 is a small-molecule selective inhibitor of LSD1.
This study is closed
Investigator
Gary Schwartz, MD
Do You Qualify?
Are you 12 years or older? Yes No
Do you have a confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies? Yes No
Are you able to provide a tumor sample? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE